Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Cutter

Showing results (201-210 of 333) with videos related to

Pageof 34
Sort By:
The Plant Journal : for Cell and Molecular Biology|September 6, 2019
Fertility restoration of maize CMS-C altered by a single amino acid substitution within the Rf4 bHLH transcription factorJennifer S Jaqueth, Zhenglin Hou, Peizhong Zheng, et al.
Brain Stimulation|January 10, 2017
The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's diseaseElizabeth L Birchall, Harrison C Walker, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.
BMC Neurology|October 10, 2024
Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosisRobert Motl, Whitney Neal, Deborah Backus, et al.
JAMA Network Open|April 13, 2026
Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia GravisJoseph Lord, Matthew Walton, Peter Murphy, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2023
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosisEva M Strijbis, Eline Coerver, Jop Mostert, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Risk tolerance to MS therapies: Survey results from the NARCOMS registryRobert J Fox, Amber Salter, Joan M Alster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Neurology|February 29, 2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United StatesAhmed Z Obeidat, Yasir N Jassam, Le H Hua, et al.
BMJ Neurology Open|June 3, 2021
Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitisBenjamin Greenberg, Patricia Plumb, Gary Cutter, et al.
Pageof 34

Showing results (201-210 of 333) with videos related to

Sort By:
Pageof 34
The Plant Journal : for Cell and Molecular Biology|September 6, 2019
Fertility restoration of maize CMS-C altered by a single amino acid substitution within the Rf4 bHLH transcription factorJennifer S Jaqueth, Zhenglin Hou, Peizhong Zheng, et al.
Brain Stimulation|January 10, 2017
The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's diseaseElizabeth L Birchall, Harrison C Walker, Gary Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 9, 2024
Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MSMarcus W Koch, Carlos Camara-Lemarroy, Eva Strijbis, et al.
BMC Neurology|October 10, 2024
Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosisRobert Motl, Whitney Neal, Deborah Backus, et al.
JAMA Network Open|April 13, 2026
Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia GravisJoseph Lord, Matthew Walton, Peter Murphy, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 12, 2023
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosisEva M Strijbis, Eline Coerver, Jop Mostert, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Risk tolerance to MS therapies: Survey results from the NARCOMS registryRobert J Fox, Amber Salter, Joan M Alster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Neurology|February 29, 2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United StatesAhmed Z Obeidat, Yasir N Jassam, Le H Hua, et al.
BMJ Neurology Open|June 3, 2021
Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitisBenjamin Greenberg, Patricia Plumb, Gary Cutter, et al.
Pageof 34